NIFTY 50
24,641.60 (-0.33%)
NIFTY IT
34,983.35 (-0.62%)
NIFTY AUTO
23,863.25 (0.32%)
NIFTY FINANCIAL SERVICES
26,380.40 (-0.36%)
NIFTY BANK
55,464.45 (-0.28%)
NIFTY REALTY
906.75 (-0.58%)
NIFTY ENERGY
34,872.35 (-0.15%)
NIFTY METAL
9,326.15 (-0.02%)
NIFTY FMCG
55,729.05 (-0.73%)
NIFTY HEALTH CARE
14,461.50 (-0.62%)
NIFTY PHARMA
21,927.40 (-1.02%)
NIFTY MEDIA
21,927.40 (-1.02%)
Platforms
Webinars
Insights
Research
Videos
Markets
Equity
Derivatives
IPO
Other Markets
Corporate Information
Pricing
Support
Backoffice
Open an Account
Home
Platform
Insights
Research
Markets
Pricing
Support
Backoffice
Open an Account
Trend of Stock Market
A trend is the broad upward or downward movement of a stock's price over time
Forthcoming IPO
Open Issues
Closed Issue
Top Gainers / Losers
52 Weeks High/ Low
Value / Volume Toppers
Get Quotes
Nifty Futures
Top Traded Quantity
Top Traded Value
Derivative Summary
Daily Settlement Price
List Of Underlying
Put Call Ratio
FII Statistics
Most Active Contract
All Index Futures
Top Gainers
Top Losers
Highest In OI
Lowest In OI
Increase In OI
Decrease In OI
Most Active Calls
Most Active Put
Top Gainers
Top Losers
Highest In OI
Lowest In OI
Increase In OI
Decrease In OI
Forthcoming Issues
Open Issues
Closed Issue
World Indices
ADR Prices
MF Investment
FII Investment
Get Quotes
Company Snapshot
Company Background
Board of Directors
Directors Reports
Profit & Loss
Balance Sheet
Quarterly Results
Shareholding Pattern
Key Financial Ratios
Mutual Fund Holdings
Peer Comparison
Technical Chart
Company News
Change Company Name
Dr Reddys Laboratories Ltd
Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
500124
ISIN Demat
INE089A01031
Book Value
345.76
NSE Symbol
DRREDDY
Dividend Yield (%)
0.65
Market Cap (
₹
Cr.)
102,269.65
P/E
14.84
EPS
82.6
Face Value
1
Date
Headline
24-Jun-25
Dr Reddys Laboratories to hold board meeting
23-Jun-25
Dr Reddys Laboratories allots 10,685 equity shares under ESOP
16-Jun-25
Dr Reddys Laboratories allots Equity shares
05-Jun-25
Alvotech and Dr Reddy's enter into collaboration and license agreement for pembrolizumab
03-Jun-25
Dr Reddys Laboratories allots 57,840 equity shares under ESOS
17-May-25
USFDA completes GMP inspection of Dr Reddy's Middleburgh facility in New York
10-May-25
Dr Reddys Laboratories AGM scheduled
09-May-25
Board of Dr Reddys Laboratories recommends Final Dividend
24-Mar-25
Dr Reddys announces cessation of subsidiary in Louisiana
22-Mar-25
Dr Reddys Laboratories to conduct board meeting
Prev
1
2
3
Next